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OBJECTIVES: Clinical-laboratory and evolutionary analysis of twenty-eight patients with Wilson’s disease.
METHODS: Twenty-eight children (twelve females and sixteen males) with Wilson’s disease were evaluated
retrospectively between 1987 and 2009, with a follow-up of 72 months (1 – 240 months). The clinical, laboratory,
and histologic features at diagnosis were recorded at the end of the study.
RESULTS: The median age at diagnosis was 11 years (2 – 18 years). Twelve patients were asymptomatic, seven had
hepatitis symptoms, five had raised aminotransferase levels, three had hepatomegaly associated with neurological
disorders, one had fulminant hepatitis with hemolytic anemia, and six patients presented with a Kayser-Fleischer
ring. A histological analysis revealed that six children had chronic hepatitis, seven had cirrhosis, two had steatosis,
one had portal fibrosis, and one had massive necrosis. The treatment consisted of D-penicillamine associated with
pyridoxine for 26 patients. Adverse effects were observed in the other two patients: one presented with
uncontrollable vomiting and the other demonstrated elastosis perforans serpiginosa. At the end of the study, all 26
treated patients were asymptomatic. Twenty-four of the patients were treated with D-penicillamine and pyridoxine,
and two were treated with trientine and zinc sulfate. A liver transplant was performed in one patient with
fulminant hepatitis, but the final patient died 48 hours after admission to the intensive care unit.
CONCLUSIONS: Family screenings associated with early treatment are important in preventing Wilson’s disease
symptoms and potentially fatal disease progression. The study suggests that Wilson’s disease must be ruled out in
children older than two years presenting with abnormal levels of hepatic enzymes because of the heterogeneity of
symptoms and the encouraging treatment results obtained so far.
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INTRODUCTION
Wilson’s disease (WD) is a rare autosomal recessive
disease that affects approximately 1 in 30,000 live births,
with a predominance in males. The disease prevalence is
higher in countries where consanguineous marriage is
frequent, such as in Turkey and Greece (1).
WD is characterized by a disturbance in copper metabo-
lism that leads to the accumulation of the metal in various
tissues of the body (1), and it is caused by mutations in the
ATP7B gene that encodes the ATP7B protein. This protein is
essential for transporting and excreting excess copper; it is
expressed mainly in the liver and kidney and, at lower levels,
in the brain, lungs, and placenta. ATP7B is a transmembrane
protein of the trans-Golgi network that incorporates free
copper into the apoceruloplasmin molecule, which in turn
transports the excess metal to the excretory vesicles of the
biliary ducts (2-6).
Copper accumulation triggers a variety of clinical mani-
festations that most often affect neurological and liver
functions, although effects have also been observed for bone,
retina, kidney, and hematological tissues. In general, hepatic
manifestations tend to occur earlier in life, whereas neuro-
logical manifestations appear after adolescence (1,7). The
symptoms rarely appear before the age of three years, and the
overall clinical picture varies from asymptomatic to acute
liver failure. Additionally, hemolysis may occur with the
formation of gallstones from the bilirubinate calculations (2).
This disease is diagnosed through clinical and family
history analysis. Methods associated with the diagnosis
include physical examinations such as ophthalmic examina-
tions, biochemical tests including the measurement of 24-
hour urinary copper levels after a penicillamine challenge
test, and analyses for genetic mutations (3,8-10). WD
treatment is based on copper chelation and symptom
control; however, in more advanced cases when liver failure
occurs, liver transplantation is the only effective treatment
(2,11).
Few reports have evaluated the clinical course of adult
Brazilian patients with WD (12), and only one study
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preliminarily evaluated pediatric patients (13). The aim of
this study was to analyze the clinical and laboratory
evolutions of WD and the effects of the standard treatments
in Brazilian children with WD.
PATIENTS AND METHODS
A retrospective study of 28 children (12 females and 16
males) with WD was conducted between 1987 and 2009.
These patients were referred to the Hepatology Unit at
the Children’s Institute at the Hospital das Clı´nicas da
Faculdade de Medicina da Universidade de Sa˜o Paulo. The
age at diagnosis ranged from 2 to 18 years (median age 11
years).
The study was approved by the Ethics Commission for
the Analysis of Research Projects of our institution under
protocol number 1026/09. Written informed consent was
obtained from the parents or guardians.
The diagnoses of WD were based on clinical and
biochemical parameters. We considered patients presenting
at least two of the following parameters to be positive for
the disease: levels of ceruloplasmin lower than 20 mg/ml in
two separate measurements, a 24-hour urinary copper level
higher than 100 mcg/24 h, or the presence of a Kayser-
Fleischer ring. Asymptomatic patients with low levels of
ceruloplasmin but with first-degree relatives (siblings or
parents) with WD were also included in the study (2).
Data obtained from medical records included medical
and family history as well as clinical examination, including
neurological assessments, presence of jaundice, hepatosple-
nomegaly, signs of liver failure, and the presence of a
Kayser-Fleischer ring through a slit lamp. Biochemical
laboratory tests evaluated at the beginning and end of the
study were: hemoglobin (Hb) (g/dl), hematocrit (Ht) (%),
white cell count (WCC) (/mm3), platelets (plat) (/mm3),
aspartate aminotransferase (AST) (U/L), alanine transami-
nase (ALT) (U/L), gamma-glutamyltransferase (GGT) (U/
L), alkaline phosphatase (APhos) (U/L), international
normalized ratio (INR), total bilirubin (TB), direct bilirubin
(DB), albumin (Alb) (g/dl), ceruloplasmin (mg/ml), 24-hour
urinary copper levels (mcg), urinary copper levels after a
penicillamine challenge test (14 patients), abdominal ultra-
sonography, and liver biopsy. The ceruloplasmin levels in
the serum were measured by radial immunodiffusion
(normal range 20–60 mg/dL). The urinary copper and
urinary copper after D-penicillamine sensitization were
measured after the urine was collected in an acid-washed,
plastic, metal-free container. The sensitization test with D-
penicillamine was performed after the patients ingested
500 mg of D-penicillamine at time zero and again after
12 hours while the 24-hour urinary copper collection
progressed. The copper levels in the urine were determined
by atomic absorption spectrophotometry.
Histopathological analyses were performed on seventeen
patients using reticulin staining, Masson trichrome stains,
hematoxylin and eosin, and the qualitative detection of
copper in the tissues. All patients selected for the study
were excluded for other diseases such as viral hepatitis,
autoimmune hepatitis, deficiency of alpha-1 antitrypsin,
and illicit drug use.
Treatment
The initial treatment consisted of D-penicillamine
(20 mg/kg/day) and pyridoxine (25–50 mg/day) for the
26 patients. Trientine (550-750 mg/day) and zinc sulfate
(300–450 mg/day) were administered to patients who
presented adverse reactions to D-penicillamine.
Data analysis
The laboratory data were analyzed using SAS (Statistical
Analysis System, version 9.3, SAS Institute, carry, NC,
USA). A t-test was used to evaluate the mean change in the
laboratory tests from the baseline to the end of the study.
RESULTS
The analyses of the medical records of 28 WD patients are
presented in Table 1. The data revealed that 12 (42.8%) of the
patients were asymptomatic (diagnosed by family screening),
seven (25.0%) presented clinical features of hepatitis, one
(3.5%) had signs of liver failure and acute hemolytic anemia
with a positive Coombs test, five (17.8%) had abnormal liver
enzymes and biochemical test results, and three (10.7%) had
hepatosplenomegaly and neurological signs, such as cere-
bellar disturbances, dysarthria, tremors, and postural
instability. In six patients (21.8%), we observed the presence
of a Kayser-Fleischer ring and of these patients, four (66.7%)
had signs of hepatitis, one (16.7%) displayed liver failure and
hemolytic anemia, and one (16.7%) was asymptomatic.
Table 1 shows the clinical and biochemical data from the
patients when they entered in study. Table 2 shows the
clinical manifestations of the 16 symptomatic patients
diagnosed with WD. Table 3 shows the diagnostic biochem-
ical laboratory results collected initially and those collected at
the end of the study. The tests that showed significant results
were: Hb (p= 0.0014), Ht (p= 0.0062), AST (p,0.0001), ALT
(p,0.0002), GGT (p,0.0026), DB (p= 0.0041), APhos
(p= 0.0005), and Alb (p= 0.0374) (Table 4).
The median and range of the ceruloplasmin levels were
3 mg/dl (1–11 mg/dl). In 22 (78.5%) patients who under-
went the 24-hour urinary copper test, the levels were 312
(53–2294) mcg/24 h. In 6 cases, the diagnosis was based on
the presence of low levels of ceruloplasmin; three of these
patients (50.0%) displayed a Kayser-Fleischer ring, and the
Table 1 - Clinical and biochemical data obtained from the
Wilsons disease patients (n = 28).
Family screening 12 (42.8%)
Abnormal hepatic enzymes 5 (17.8%)
Symptoms of hepatitis 7 (25%)
Hepatosplenomegaly + neurological symptoms 3 (10.7%)
Fulminant hepatitis + hemolytic anemia
(Coombs positive)
1 (3.5%)
Table 2 - Clinical manifestations of symptomatic Wilsons
disease patients at diagnosis (n = 16).
Jaundice 8 (50%)
Hepatosplenomegaly 7 (43.7%)
Abdominal pain 6 (37.5%)
Vomiting 5 (31.2%)
Fatigue 3 (18.7%)
Choluria 7 (43.7%)
Hipocholia/Acholia 4 (25%)
Ascites 6 (37.5%)
Edema of lower limbs 6 (37.5%)
GI bleeding 3 (18.7%)
Abbreviation: Gastrointestinal bleeding (GI bleeding).
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other three (50.0%) were siblings of WD patients. In 11
patients displaying normal urinary copper levels, the test
for sensitization with D-penicillamine revealed urinary
copper levels that were higher than 1,600 mcg/24 h.
Histopathology revealed portal fibrosis in one patient
(5.8%), massive necrosis in one patient (5.8%), liver steatosis
in two patients (11.7%), chronic hepatitis in six patients
(35.3%), and cirrhosis in seven patients (41.1%).
Twenty-six patients began treatment with D-penicillamine
and pyridoxine. However, two of the patients (7.7%) had
adverse effects: one had uncontrollable vomiting after four
months of treatment, and the other had elastosis perforans
serpiginosa (EPS) after 72 months. The patients were then
treated with trientine and zinc sulfate, which produced a
good outcome in both patients. In five patients (19.2%) with
no adverse effects, zinc sulfate was added to the D-
penicillamine treatment because although D-penicillamine
preserved hepatic function, the liver enzymes continued to be
abnormal after one year of treatment. The introduction of
zinc sulfate normalized the liver enzymes of four patients,
and one patient remained with minimal change. At the end of
the study, 24 patients showed normalized levels of liver
enzymes and only two continued to present abnormal
results. These two patients had preserved liver functions.
Nineteen patients continued the medication initially pre-
scribed for an average interval of 56.4 months (ranging from 4
to 120 months), and all of them achieved eradication of the
WD symptoms and demonstrated normal laboratory test
results.
The mean follow-up at the end of the study was 72
months (one patient was followed for 240 months). Twenty-
six patients (92.8%) remained asymptomatic. Of these
patients, 24 (92.3%) displayed normal liver enzymes, but
two (7.7%) showed abnormal liver enzymes while main-
taining normal hepatic function. We observed a significant
normalization of the hematological and biochemical test
results.
We detected complications in some patients during the
course of the disease and treatment. One patient had
bilateral renal lithiasis associated with hydronephrosis two
years after the diagnosis, and one patient had micro and
macroscopic hematuria. One patient underwent liver
transplantation and was followed up for 18 months (end
of the study), and one patient died 48 hours after entry into
the ICU for sepsis. This patient had severe hepatic failure,
hepatic encephalopathy, and sepsis. The diagnosis of WD
was based on lab test results that arrived after the time of
death.
DISCUSSION
Studies of WD in childhood are limited because the
number of patients available to compose a relevant study is
Table 3 - Laboratory findings of the WD patients at time of diagnosis and at the end of the study.
Variable No. of Patients N mean std median Min max
Hb(g/dl) basal 27 12.45 1.54 12.60 6.10 14.60
end of study 27 13.62 2.38 13.50 6.80 19.70
Ht(%) basal 27 37.24 4.81 38.30 17.10 43.50
end of study 27 39.56 6.18 40.00 17.30 49.40
WBC(/mm3) basal 25 6254.00 2801.04 6600.00 2200.00 13500.00
end of study 26 5930.00 2528.08 5800.00 2600.00 15100.00
Plat(/mm3) basal 26 236000.00 131970.75 210000.00 70000.00 531000.00
end of study 26 211000.00 119184.64 184000.00 32000.00 428000.00
AST(U/L) basal 26 89.42 65.21 69.50 15.00 301.00
end of study 26 25.46 13.89 21.50 10.00 73.00
ALT(U/L) basal 26 127.00 112.30 100.00 16.00 457.00
end of study 26 37.00 25.58 33.50 7.00 105.00
GGT(U/L) basal 26 85.98 105.20 50.75 15.00 530.00
end of study 25 30.38 29.88 24.00 7.00 160.00
APhos(U/L) basal 25 464.80 264.43 380.00 67.00 1054.00
end of study 25 256.50 209.57 169.00 41.00 885.00
TB(g/dl) basal 23 1.04 0.70 0.70 0.31 3.00
end of study 23 0.85 0.51 0.79 0.11 2.20
DB(g/dl) basal 23 0.45 0.40 0.30 0.05 1.70
end of study 23 0.19 0.10 0.20 0.02 0.40
Alb(g/dl) basal 19 3.79 0.93 3.80 1.50 5.30
end of study 19 4.31 0.47 4.27 3.10 5.53
INR basal 21 1.34 0.26 1.25 0.97 1.91
end of study 21 1.24 0.21 1.14 1.01 1.68
Abbreviations: hemoglobin (HB) (g/dl), hematocrit (HT) (%), white cell count (WCC) (/mm3), Platelets (PLAT) (/mm3), aspartate aminotransferase (AST) (U/
L), alanine transaminase (ALT) (U/L), gamma-glutamyltransferase (GGT) (U/L), alkaline phosphatase (APhos) (U/L), total bilirubin (TB) (mg/dl), albumin
(Alb) (g/dl), international normalized ratio (INR).
Table 4 - Laboratory data – Change from baseline.
Variable No. of Patients
Pr.F
(t test)*
Hb(g/dl) 27 0.0014
Ht(g/dl) 27 0.0062
AST(U/L) 26 ,0.0001
ALT(U/L) 26 ,0.0002
GGT(U/L) 26 ,0.0026
TB(g/dl) 23 0.1998
DB(g/dl) 23 0.0041
WBC(/mm3) 25 0.5396
INR 21 0.2578
Aphos(U/L) 25 0.0005
Plat(/mm3) 26 0.1549
Alb(g/dl) 19 0.0374
*t test for the hypothesis: H0: mean change (end of the study –
baseline) = 0.
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frequently low, which precludes large cohort studies or
randomized controlled trials. Although reports on pediatric
WD patients from other countries have been published, only
one study has been published on Brazilian children (13).
Machado et al. (2006) evaluated 119 Brazilian patients,
mostly adults, with a mean age at diagnosis of 19.3 [7–37]
and reported that the major initial clinical manifestation was
neurological (12). In our study, patients were diagnosed at a
mean age of 10 years, and most did not have any
neurological symptoms.
The diagnosis of WD is usually established by biochemical
testing following clinical suspicion. There is no single
diagnostic test that can exclude or confirm WD with
certainty. A diagnosis of WD should be based on a
combination of clinical features, laboratory findings, and
mutation analysis (1). For cases of doubtful diagnosis even
after biochemical testing, molecular genetic analyses are used
to identify disease-causing alleles (14). In our study, most of
the cases were clinically diagnosed after three years of age,
and only those with a family history were screened and had a
diagnosis confirmed earlier. Although we did not perform
the genetic test, the data from the literature do not show a
correlation between genotype and age at diagnosis, serum
ceruloplasmin levels, presence of cirrhosis or disease (1).
One of the clinical criteria for the diagnosis of WD is the
Kayser-Fleischer ring, which is more common in adults than
in children (15). Although this is considered a strong sign,
only 21.4% of the patients in our study actually presented
with the ring, and only one showed any neurological
symptoms associated with the ring. This result is in
accordance with results of other studies (16-18).
The biochemically abnormal ceruplasmin levels helped us
to diagnose the disease, but normal values are frequently
observed in WD patients (1,10). Indeed, we found that four
patients (14.2%) showed normal ceruplasmin values, and
the diagnosis was only possible because we detected high
levels of urinary copper after the 24-hour urinary copper
test, observed the presence of the Kayser Fleischer ring, or
observed improvement in the liver enzymes after the
initiation of treatment. Sometimes, even with reduced levels
of ceruloplasmin, the 24-hour urinary copper levels are not
always elevated. When this happens, sensitization with D-
penicillamine is one way to confirm the diagnosis (10,17-19).
A study by Muller et al. comprising 38 children with WD
found that sensitization with D-penicillamine had a speci-
ficity of 92.8% and a sensitivity of 88.2% (19).
WD encompasses asymptomatic patients, patients pre-
senting changes in biochemical tests only, and patients with
acute liver failure, both with and without hemolytic anemia.
The clinical features in our study were mild and different
from those of other pediatric reports, which have mostly
included WD children with acute liver failure or chronic
symptomatic liver disease (2,10,14,18). This heterogeneity of
WD symptoms, and the encouraging treatment results
obtained so far, suggest that families and clinicians should
be watchful of patients older than three years. In our study,
all symptomatic patients presented initial signs of liver
involvement or had abnormal liver enzyme measurements,
which was expected given the history of the disease and the
age of the patients. We show in this study that patient
screening based on a family history of WD can enable early
diagnosis before the onset of symptoms, thereby leading to a
successful outcome following treatment.
We observed a low percentage of patients with neurological
symptoms, which was expected because such characteristics
are most commonly found in adults (20). For pediatric WD
patients, deterioration in school performance, impulsive
behavior, and even a loss of motor coordination, dysarthria,
dystonia, spasticity, tremor, depression, psychosis, and
personality disorders have been reported (11,12,15).
A retrospective study involving 25 pediatric WD patients
with renal symptoms revealed that such manifestations are
often undiagnosed and poorly reported and that they
mostly present later in the course of the disease (21).
These findings may be explained by the disease itself as well
as the adverse effects of D-penicillamine (21,22). In all cases,
it is advisable to perform total abdominal ultrasound and
renal function biochemical tests to help diagnose and follow
up the patients. In our study, renal manifestations were
unusual.
The drugs available to treat WD are D-penicillamine,
trientine, and zinc. The treatment is life-long and is usually
associated with a diet low in copper. The most potent drug,
D-penicillamine, is a derivative of penicillin that forms a
soluble copper compound that can then be eliminated in the
urine (23). Deficiency of copper arising from the treatment
was not observed in any of our patients, in agreement with
the findings in the literature (24). Despite its chelating
action, D-penicillamine may induce metallothionein in the
liver, leading to reduced copper levels and consequently
reduced toxic effects (24). Because D-penicillamine can
cause a deficiency in pyridoxine levels, a prophylactic dose
of vitamin B6 is usually given to WD patients being treated
with this drug (25).
Vega et al. analyzed children with WD after one year of
treatment with D-penicillamine and found a normalization
of the enzymatic test. However, they also showed that in
patients with severe disease, normalization of albumin
levels and coagulation are obtained later in the course of
the treatment (24).
In our study, two patients were treated with trientine as
an alternative therapy to D-penicillamine. Although it is a
less potent chelator, trientine is recommended in case of
adverse reactions to D-penicillamine (24). Another alter-
native drug is zinc, which interferes with the intestinal
absorption of copper. In enterocytes and hepatocytes, zinc
induces the synthesis of a copper-binding ligand, probably a
thionein, which sequesters copper from the nutrient
medium, making it unavailable for serosal transfer (24).
This complex is then eliminated in the shedding of the
gastrointestinal tissue. Currently, zinc is used to maintain
asymptomatic patients with prolonged use of D-penicilla-
mine or trientine (18). Brewer et al. (2005) reported a
successful experience using zinc acetate to treat a group of
34 children (26). The results presented here also show a
satisfactory response to WD treatment using zinc.
Regarding the adverse reactions induced by D-penicilla-
mine, Vega et al. reported that toxic effects of the drug
affected 10–20% of patients, usually early on in the treatment
(24). One of the common adverse reactions observed is EPS,
which usually presents as annular lesions consisting of
hyperkeratotic reddish-brown papules arranged in a semi-
circle, with a central area of atrophic skin (27,28). EPS affects
mainly the patient’s neck and upper limbs, and less fre-
quently the axils, thighs, heels, and penis (28). In most cases,
EPS occurs after long periods of use (mean 11.3 years)
of D-penicillamine (29-31). EPS may be stopped by the
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administration of zinc and trientine, as suggested by Be´cuwe
et al. (27). The presence of EPS is unusual in pediatric patients.
We did, however, observe a single patient with this adverse
effect following the use of D-penicillamine for 5 years. We
proceeded with monotherapy with zinc sulfate, which
produced good outcomes as the patient showed no worsening
of clinical signs or laboratory findings. However, although
treatments with zinc salts can be effective in most patients
with WD, chelating agents are better at preventing hepatic
deterioration (27).
Liver transplantation (LT) can save the lives of patients
with WD who present with hepatic failure or chronic liver
disease and are unresponsive to other medical treatments.
Few reports have evaluated the outcomes of children and
adults after LT for WD. Recently, Arnon et al. demonstrated
that LT was an excellent treatment option for patients with
WD (32). In our study, the single patient that received liver
transplantation showed a favorable outcome.
We conclude that WD should be diagnosed by consider-
ing the family and clinical history as well as information
from the biochemical laboratory tests because of the
heterogeneity of the symptoms and the occurrence of
asymptomatic patients. Additionally, children who are
older than two years and have a family history of WD or
increased hepatic enzyme levels and symptoms of acute
hepatitis without any etiological viral markers or auto-
immunity should be routinely screened for WD. Early
diagnosis accompanied by the initiation of therapy with
copper chelators, zinc salts, or even liver transplantation are
essential for favorable outcomes, such as preventing
morbidity and mortality.
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